UK’s NICE Goes Ahead With Parkinson’s Product Funding But Pending Real-World Data
Executive Summary
Five remote monitoring medical devices that have “transformational” potential for Parkinson’s disease are to be conditionally funded via the UK’s National Health Service in a drive to address clinical and cost-effectiveness uncertainties using data from real patients.
You may also be interested in...
UK Govt Under Fire From Pharma Industry Over Statutory Pricing Scheme Changes
The UK’s pharmaceutical industry association, the ABPI, claims that “fundamental failures” in the government’s consultation and impact assessment for proposed changes to the branded medicines statutory pricing scheme could be grounds for legal challenge.
EU Needs Better Data Tools To Combat Vaccine-Preventable Cancers, Says Industry
Data on vaccine coverage rates and trends in vaccine-preventable disease incidence in the EU are crucial but are often not available or inaccurate, according to EFPIA subgroup Vaccines Europe.
Orchard On The Trials, Tribulations And Triumphs Of Gene Therapy HTA
Convincing payers to fund a $3m therapy is no mean feat, even for innovations with curative potential. Orchard Therapeutics, a company with much experience in this field, tells the Pink Sheet why it values open dialogues, and outlines how health technology assessment methods could be improved.